Molecule
Tildrakizumab is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Tildrakizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ILUMYA is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. active psoriatic arthritis in adult patients.
Source: US FDA prescribing information
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
Source: US FDA prescribing information
See the full prescribing information for recommended evaluations and immunizations prior to treatment. Administer ILUMYA by subcutaneous injection. Recommended dosage: Moderate-to-Severe Plaque Psoriasis 100 mg at Weeks 0, 4, and every 12 weeks thereafter. Active Psoriatic Arthritis For adult patients with active psoriatic arthritis and coexistent moderate-to-severe plaque psoriasis, the recommended dosage is the same as in adults with moderate-to-severe plaque psoriasis. For other adult patients with active psoriatic arthritis: 100 mg every 12 weeks.
Source: US FDA prescribing information
ILUMYA is contraindicated in patients with a history of serious hypersensitivity reaction to tildrakizumab or to any of the excipients. Serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
Source: US FDA prescribing information
Hypersensitivity: If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. Infections: ILUMYA may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, consider discontinuing ILUMYA until the infection resolves. Pretreatment Evaluation for Tuberculosis (TB): Evaluate for TB prior to initiating treatment. Immunizations: Avoid use of live vaccines.
Source: US FDA prescribing information
The following serious adverse reactions are discussed elsewhere in the labeling: Hypersensitivity Reactions Infections Most common adverse reactions associated with ILUMYA treatment are Plaque Psoriasis (≥1%): upper respiratory infections, injection site reactions, and diarrhea. Psoriatic Arthritis (≥3%): upper respiratory tract infections and COVID-19.
Source: US FDA prescribing information
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until the time of use. Do not freeze. ILUMYA can be kept at room temperature at 25°C (77°F) for up to 30 days in the original carton to protect from light. Once stored at room temperature, do not place back in the refrigerator. Do not store ILUMYA above 25°C (77°F). Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Tildrakizumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ilumya 100 mg/1 mL injectionSubcutaneous Cold chain | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
| Ilumya 100 mg/mL injectionSubcutaneous Cold chain | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
1 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Tildrakizumab and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 1 brand names for Tildrakizumab, including Ilumya.
Yes. The US FDA first approved Tildrakizumab on 20 March 2018, according to Drugs@FDA.
Yes. Tildrakizumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Tildrakizumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tildrakizumab is classified under ATC code L04AC17 (Tildrakizumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.